Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Supernus Pharmaceuticals (SUPN) Non-Current Debt (2021)

Supernus Pharmaceuticals has reported Non-Current Debt over the past 4 years, most recently at $379.3 million for Q4 2021.

Quarterly Non-Current Debt changed N/A to $379.3 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $379.3 million through Dec 2021, changed N/A year-over-year, with the annual reading at $379.3 million for FY2021, N/A changed from the prior year.
Non-Current Debt was $379.3 million for Q4 2021 at Supernus Pharmaceuticals, up from $8.0 million in the prior quarter.
Over five years, Non-Current Debt peaked at $379.3 million in Q4 2021 and troughed at $379.3 million in Q4 2021.